
    
      The maximum study duration per participant was to be of approximately 20 weeks that consisted
      of an up to a 4-week screening and CGM training period including a 1-2 week baseline
      (blinded) CGM performance (allowed for re-training), a 14-week open-label, comparative
      treatment period allowing for dose titration in both basal and meal-time insulin and
      including a 1-2 week end-of treatment blinded CGM collection with fixed dose of HOE901-U300
      and Lantus, and a 2 day post treatment follow-up period.
    
  